Kornitzer Capital Management Inc. KS boosted its stake in shares of AstraZeneca plc (NYSE:AZN) by 48.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,100 shares of the company’s stock after acquiring an additional 27,000 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in AstraZeneca were worth $3,704,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Parallel Advisors LLC boosted its position in shares of AstraZeneca by 10.7% during the third quarter. Parallel Advisors LLC now owns 11,636 shares of the company’s stock valued at $519,000 after buying an additional 1,125 shares during the period. Cullen Frost Bankers Inc. boosted its position in shares of AstraZeneca by 24.1% during the third quarter. Cullen Frost Bankers Inc. now owns 280,996 shares of the company’s stock valued at $12,524,000 after buying an additional 54,488 shares during the period. Synovus Financial Corp boosted its position in shares of AstraZeneca by 28.6% during the third quarter. Synovus Financial Corp now owns 91,179 shares of the company’s stock valued at $4,060,000 after buying an additional 20,261 shares during the period. Atlas Capital Advisors LLC boosted its position in shares of AstraZeneca by 3.2% during the third quarter. Atlas Capital Advisors LLC now owns 21,439 shares of the company’s stock valued at $956,000 after buying an additional 655 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of AstraZeneca by 6.8% during the third quarter. Russell Investments Group Ltd. now owns 1,958,492 shares of the company’s stock valued at $87,492,000 after buying an additional 123,962 shares during the period. 17.54% of the stock is currently owned by institutional investors.
Shares of NYSE AZN traded up $0.46 during trading hours on Friday, reaching $47.26. The stock had a trading volume of 5,329,322 shares, compared to its average volume of 4,158,044. The company has a current ratio of 0.92, a quick ratio of 0.70 and a debt-to-equity ratio of 1.29. The firm has a market cap of $122.79 billion, a price-to-earnings ratio of 27.32, a P/E/G ratio of 1.53 and a beta of 0.48. The business’s fifty day moving average price is $45.32 and its two-hundred day moving average price is $42.22. AstraZeneca plc has a 52-week low of $35.30 and a 52-week high of $49.22.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.05. The firm had revenue of $6.13 billion during the quarter, compared to analyst estimates of $6.07 billion. AstraZeneca had a return on equity of 38.63% and a net margin of 8.42%. AstraZeneca’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.71 earnings per share. Equities research analysts anticipate that AstraZeneca plc will post 1.81 earnings per share for the current fiscal year.
AZN has been the subject of several recent analyst reports. Argus boosted their target price on AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. HSBC restated a “sell” rating on shares of AstraZeneca in a research report on Thursday, October 17th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday. Citigroup restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 29th. Finally, ValuEngine lowered AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $46.53.
In other news, major shareholder Plc Astrazeneca purchased 425,000 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was purchased at an average price of $19.00 per share, for a total transaction of $8,075,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What is the quiet period?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.